NeoGenomics, Inc. (NEO) SEC Filings & Earnings Calls

CEO transition could cause short-term uncertainty, but planned succession mitigates risk.

“Planned succession with internal promotion.”

Key executive departure may create transitional risk in legal and business development functions.

“EVP, General Counsel & Business Development departing; separation payments triggered.”

DOJ civil settlement finalized; consulting services investigation resolved.

“Finalized a civil settlement with the Department of Justice resolving a self-disclosed matter and investigation concerning consulting services provided by the Company.” · word for word

Convertible debt adds leverage; $316M notes due 2032 at 0.75%.

“completion of a $316 million private offering of 0.75% convertible senior notes due 2032” · word for word

Pharmaceutical Clinical Trial Slowdown

“lower non-clinical revenue due to macro clinical trial trends in the pharmaceutical industry” · word for word

Regulatory Risk for LDTs

“future legislative, regulatory, or administrative actions could reintroduce FDA oversight of certain LDTs, which could increase compliance obligations and costs” · word for word

Tariff Impact

“We may experience increased supply chain challenges and customer demand uncertainty due to rapid changes in global trade policies” · word for word

Legal overhang resolved; settlement amount below accrued reserve, indicating no additional financial hit.

“Settlement $9.8M vs reserve $11.2M; no admission of liability.”

Dilution risk if stock price exceeds conversion price; capped calls provide partial offset.

“Conversion price $14.16, cap price $20.98; capped calls cost $28.7M.”

Potential dilution from future conversion of notes.

“Offering of convertible notes implies potential equity dilution.”

Potential dilution from future conversion.

“Proposed convertible notes offering.”

Potential dilution from future equity grants under the amended plan.

“5,000,000 additional shares authorized.”

Dependence on reimbursement coverage for new tests; MolDX decision is favorable but limited to PanTracer LBx.

“Announced a favorable MolDX coverage decision for PanTracer™ LBx” · word for word

Competitive market for MRD testing; RaDaR ST faces established competitors.

“Launched RaDaR® ST, a circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD), which we estimate represents a $20 billion addressable market, growing at 30% annually, which we believe is less than 10% penetrated.” · word for word

LDT Regulation Uncertainty

“Notwithstanding the court’s decision, future legislative, regulatory, or administrative actions could reintroduce FDA oversight of certain LDTs, which could increase compliance obligations and costs.” · word for word

Tariff Impact on Supply Chain

“We may experience increased supply chain challenges and customer demand uncertainty due to rapid changes in global trade policies, which may impact our net sales and profitability.” · word for word

CEO transition risk

“CEO transition following the decision by our then CEO, Mr. Smith, to retire effective April 1, 2025.” · word for word

Stockholder compensation concerns

“In 2025, we received 81.77% support for our annual say-on-pay proposal.” · word for word

Equity dilution risk

“increase the number of shares of common stock reserved for issuance under the 2023 Equity Incentive Plan by 5,000,000 shares to 13,300,000 shares.” · word for word

Net loss increased 37% in FY2025 to $108M, though expected to narrow in FY2026.

“Full year net loss increased 37% to $108 million” · word for word

Non-clinical revenue impacted by macro trends in pharma/biotech.

“lower non-clinical revenue due to macro trends in the pharmaceutical and biotech industries” · word for word

Regulatory Risk - LDT Oversight

“On March 31, 2025, the U.S. District Court for the Eastern District of Texas vacated the FDA's final rule in its entirety... future legislative, regulatory, or administrative actions could reintroduce FDA oversight of certain LDTs, which could increase compliance obligations and costs.” · word for word

Impairment Risk on Acquired Assets

“Impairment charges consisted of an $11.4 million impairment on InVisionFirst®-Lung intangible assets, $15.9 million impairment on the disposal of substantially all of Trapelo's assets.” · word for word

Cash Burn / Liquidity Risk

“Cash and cash equivalents, end of year $159,618, down from $367,012 at beginning of year, primarily due to repayment of $201.3M convertible notes.” · word for word

Preliminary results are unaudited and subject to change, which may be material.

“The selected financial results are based on preliminary unaudited information and management estimates, are not a comprehensive statement of the Company’s financial results ... and are subject to change. Such changes may be material.” · word for word

Non-clinical revenue weakness persists, but anticipated and incorporated in guidance.

“Continued weakness in non-clinical revenue, which we anticipated and incorporated into the full-year guidance.” · word for word

Impairment charge from Trapelo sale indicates potential asset write-downs.

“$7.1 million of impairment charges from impairment of assets held for sale related to the planned sale of Trapelo.” · word for word

Impairment risk from InVisionFirst-Lung and disposal group

“Impairment charges consisted of an $11.4 million impairment on InVisionFirst®-Lung intangible assets, a $15.3 million impairment on the disposal group held for sale, and a $0.4 million loss on InVisionFirst®-Lung inventory write-off.” · word for word

Tariff and trade policy risk

“In addition, we are monitoring the effects of recently implemented tariffs and the potential imposition of modified or additional tariffs. We may experience increased supply chain challenges and customer demand uncertainty due to rapid changes in global trade policies, which may impact our net sales and profitability.” · word for word

Clinical trial revenue slowdown

“Revenues from the Pathline acquisition also contributed to revenue growth, which was partially offset by lower non-clinical revenue due to macro clinical trial trends in the pharmaceutical industry, and a less favorable test mix.” · word for word

Cash burn from convertible note repayment

“This change was primarily due to $201.3 million cash used for the repayment of the convertible senior notes.” · word for word